Items tagged with Medicines
TB drug may work better than others in its class (post)
Computer simulations suggest moxifloxacin outperforms two other drugs when doses are missed
CURE Pharmaceutical subsidiary, Oak Therapeutics, completes critical milestone in Phase 1 of NIH grant to develop oral dissolvable strip for TB (post)
OXNARD, Calif., Aug. 22, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its subsidiary company, Oak Therapeutics, has completed a critical milestone of its Phase I Small Business Innovative Research Contract (SBIR) from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/ NIAID) to develop a formulation for 300 mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip (ODS) as an anti-tuberculosis treatment option.
NIAID supports clinical testing of anti-cancer drug for TB (post)
The National Institute of Allergy and Infectious Diseases has awarded a three-year $5 million grant to an international team of investigators to test the anti-cancer drug imatinib as a repurposed treatment for tuberculosis. The study will take place at Emory University in Atlanta, and in South Africa at the Aurum Institute's Tembisa Clinical Research Center in South Africa.
Otsuka and Mylan announce license agreement to commercialize delamanid (Deltyba™) for MDR-TB in high-burden countries (post)
TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba™.
IDRI to continue development of inhalable TB drug candidate (post)
SEATTLE | Aug. 24, 2017 - IDRI (Infectious Disease Research Institute), on behalf of the Lilly TB Drug Discovery Initiative, announces it has entered into an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd., a China-based leading biopharmaceutical company, to continue development of inhalable CPZEN-45, a tuberculosis (TB) drug candidate that could potentially treat the growing problem of antibiotic-resistant TB. Burdening its victims with increased health concerns and a high cost of treatment, drug-resistant TB occurs when Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, becomes resistant to the drugs used to treat it, underscoring the need for the development of new drugs.
Better data on fake drugs needed to fight the scourge (post)
The problem of fake medicines is a big one. But precisely how big?
WHO prequalifies key treatment for children with TB (post)
01 September 2017 - WHO has just prequalified a two-pills-in-one paediatric medicine that is critical for the continuation phase of the six-month treatment required to cure tuberculosis (TB). The medicine – rifampicin 75mg + isoniazid 50mg – is a fixed dose combination (FDC) tablet manufactured by Macleods Pharmaceuticals Limited. WHO medicines prequalification activities are partly funded by the Bill & Melinda Gates Foundation and by Unitaid.
TB pills most effective prior to, not after, food: research (post)
A team from National Institute for Research in Tuberculosis (NIRT) examined 25 TB patients in Chennai who consumed food just before they took their medication.
Where are the innovations in tuberculosis drug discovery? (post)
WHO has released a report that highlights a serious lack of antibiotics in clinical development; a worrying finding in an era of antimicrobial resistance. The report identifies a particular shortage of antibiotics under development for multidrug-resistant tuberculosis, which is a disease that kills a quarter of a million people every year.
Unitaid commits US $21.4 million to the WHO prequalification programme (post)
Geneva, 9 October 2017 – Unitaid is investing a further US$ 21.4 million in the World Health Organization’s (WHO) prequalification programme for medicines and diagnostics.
Page 7 of 19 · Total posts: 0
←First 6 7 8 Last→